Vpliv pooperativne radioterapije pri multimodalnem zdravljenju lokalnmo napredovalega raka dojke

Show document
A+ | A- | | SLO | ENG

Title:	Vpliv pooperativne radioterapije pri multimodalnem zdravljenju lokalnmo napredovalega raka dojke
Authors:	ID But-Hadžić, Jasna (Author) ID Bilban-Jakopin, Cvetka (Author)
Files:	PDF - Presentation file, download (240,99 KB) MD5: 10BB7E024537557199A5E794B51B9051 PID: 20.500.12556/dirros/740201f0-987a-4138-b61f-d33b753a2ca2
Language:	Slovenian
Typology:	1.01 - Original Scientific Article
Organization:	OI - Institute of Oncology
Publication status:	Published
Publication version:	Version of Record
Year of publishing:	2008
Number of pages:	str. 89-93
Numbering:	Letn. 12, št. 2
PID:	20.500.12556/DiRROS-8779
UDC:	616-006
ISSN on article:	1408-1741
URN:	URN:NBN:SI:doc-FHL0FV8M
COBISS.SI-ID:	25344473
Copyright:	by Authors
Note:	BSDOCID143368;
Publication date in DiRROS:	31.08.2018
Views:	3480
Downloads:	790
Metadata:
:	Copy citation

Share:

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

License:	CC BY 4.0, Creative Commons Attribution 4.0 International

Link:	http://creativecommons.org/licenses/by/4.0/
Description:	This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:	31.08.2018

Language:	Undetermined
Title:	The impact of radiotherapy in multimodal management of locally advanced breast cancer
Abstract:	We retrospectively analyzed the data from 55 patients treated for noninflammatory locally advanced breast cancer (LABC) with neoadjuvant chemotherapy and surgery with or without radiotherapy. The mean follow-up was 55 months. The purpose was to evaluate and compare the impact of postoperative radiotherapy, whether it was indicated on the basis of clinical stage at presentation of the disease or on downstaged pathological disease after initial chemotherapy. The 3-year overall survival (OS) was 74%, disease-free survival (DFS) 73% and relapse-free survival (RFS) 87%. The OS and DFS benefit was seen in those receiving radiation, with a mean OS of 89 months vs. 68 months (p=0.029) and mean DFS of 72 months vs. 54 months (p=0.029). Total LRR was 11% (8% vs. 17% in no RT group, p=0,349) and mean RFS of 95 months vs. 86 months (p=0.164). Significantly lower OS and DFS of the patients who were not treated with radiotherapy suggest that the indication for radiation treatment should be based on clinical pre-chemotherapy stage rather than pathological post-chemotherapy stage for non-inflammatory LABC.